Article
Antibody evasion by the P.1 strain of SARS-CoV-2.
Cell - 27 May 2021
Dejnirattisai Wanwisa, Zhou Daming, Supasa Piyada, Liu Chang, Mentzer Alexander J, Ginn Helen M, Zhao Yuguang, Duyvesteyn Helen M E, Tuekprakhon Aekkachai, Nutalai Rungtiwa, Wang Beibei, López-Camacho César, Slon-Campos Jose, Walter Thomas S, Skelly Donal, Costa Clemens Sue Ann, Naveca Felipe Gomes, Nascimento Valdinete, Nascimento Fernanda, Fernandes da Costa Cristiano, Resende Paola Cristina, Pauvolid-Correa Alex, Siqueira Marilda M, Dold Christina, Levin Robert, Dong Tao, Pollard Andrew J, Knight Julian C, Crook Derrick, Lambe Teresa, Clutterbuck Elizabeth, Bibi Sagida, Flaxman Amy, Bittaye Mustapha, Belij-Rammerstorfer Sandra, Gilbert Sarah C, Carroll Miles W, Klenerman Paul, Barnes Eleanor, Dunachie Susanna J, Paterson Neil G, Williams Mark A, Hall David R, Hulswit Ruben J G, Bowden Thomas A, Fry Elizabeth E, Mongkolsapaya Juthathip, Ren Jingshan, Stuart David I, Screaton Gavin R
Abstract excerpt
Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates. However, new strains have emerged with multiple mutations, including P.1 from Brazil, B.1.351 from South Africa, and B.1.1.7 from the UK (12, 10, and 9 changes in the spike, respectively). All have mutations in the ACE2 binding site, with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.